Compounds to treat inherited retinal disease
AssigneeUniversiteit Gent
InventorsFrauke Coppieters, Alfredo Duenas Rey, Manon Bouckaert
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversiteit Gent
InventorsFrauke Coppieters, Alfredo Duenas Rey, Manon Bouckaert
Estimating the term…
A field of treating inherited retinal disease (IRD). More specifically, the disclosure discloses a target region that is useful to screen for compounds capable of treating inherited retinal disease and discloses specific antisense oligonucleotides (ASOs) useful to treat the latter disease. This disclosure is based on the finding that the variant c.-123C>T in the 5′UTR of the RDH12 gene causes an upstream start codon (uATG) resulting in insufficient RDH12 protein production and hence causes inherited retinal disease. ASOs, which hybridize with a region surrounding or containing the uATG provide steric hindrance for recognition of the upstream start codon, thus redirecting the scanning ribosomes to the primary start codon, which results in increased RDH12 protein production.
1-7. (canceled)
An antisense oligonucleotide (ASO) comprising a polynucleotide that hybridizes under stringent conditions to a region of the RDH12 gene 5′ untranslated region (5′UTR) containing the variant c.-123C>T, wherein the ASO is capable of increasing translation of RDH12 protein.
An antisense oligonucleotide (ASO) comprising means for increasing translation of RDH12 protein in a cell comprising variant c.-123C>T in the 5′UTR of the RDH12 gene,
A method of screening a molecule for the ability to increase translation of RDH12 protein, the method comprising:
Dependencies are inferred from the claim text.